Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor

AIM: To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations. METHOD: Western...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Bain, Gretchen, King, Christopher D., Schaab, Kevin, Rewolinski, Melissa, Norris, Virginia, Ambery, Claire, Bentley, Jane, Yamada, Masanori, Santini, Angelina M., van de Wetering de Rooij, Jeroen, Stock, Nicholas, Zunic, Jasmine, Hutchinson, John H., Evans, Jilly F.
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2013
Assuntos:
Pharmacodynamics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575944/
https://ncbi.nlm.nih.gov/pubmed/22803688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04386.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares